

Open-label, randomised controlled, phase 3 trial.  
Patients with CD were randomized to tight control vs Clinical management  
(based on symptoms).  
1<sup>st</sup> 8w prednisone induction+ escalated in stepwise: ADA +/-AZA.

Primary endpoint: mucosal healing (CDEIS<4) w48

Secondary endpoints: deep remission; biological remission; CDEIS<4;  
complete endoscopic remission; endoscopic response; steroid free  
remission, clinical remission.

#### Results:

- Mucosal healing w48: 46% Tight control vs 30% clinical; p=0.01
- 2% tight control vs 20% clinical, needed rescue therapy.
- 76% tight control vs 74% clinical completed the study.

#### Conclusions:

Timely escalation with an antiTNF on the basis of clinical symptoms and biomarkers in patients with early CD results in better clinical and endoscopic outcomes than symptom-driven decisions alone.

